Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta
- PMID: 25944380
- PMCID: PMC4795106
- DOI: 10.1038/ejhg.2015.81
Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta
Erratum in
-
Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta.Eur J Hum Genet. 2015 Aug;23(8):1112. doi: 10.1038/ejhg.2015.129. Eur J Hum Genet. 2015. PMID: 26177859 Free PMC article. No abstract available.
Abstract
Osteogenesis imperfecta (OI) is a rare hereditary bone fragility disorder, caused by collagen I mutations in 90% of cases. There are no comprehensive genotype-phenotype studies on >100 families outside North America, and no population-based studies determining the genetic epidemiology of OI. Here, detailed clinical phenotypes were recorded, and the COL1A1 and COL1A2 genes were analyzed in 164 Swedish OI families (223 individuals). Averages for bone mineral density (BMD), height and yearly fracture rate were calculated and related to OI and mutation type. N-terminal helical mutations in both the α1- and α2-chains were associated with the absence of dentinogenesis imperfecta (P<0.0001 vs 0.0049), while only those in the α1-chain were associated with blue sclera (P=0.0110). Comparing glycine with serine substitutions, α1-alterations were associated with more severe phenotype (P=0.0031). Individuals with type I OI caused by qualitative vs quantitative mutations were shorter (P<0.0001), but did not differ considering fractures or BMD. The children in this cohort were estimated to represent >95% of the complete Swedish pediatric OI population. The prevalence of OI types I, III, and IV was 5.16, 0.89, and 1.35/100 000, respectively (7.40/100 000 overall), corresponding to what has been estimated but not unequivocally proven in any population. Collagen I mutation analysis was performed in the family of 97% of known cases, with causative mutations found in 87%. Qualitative mutations caused 32% of OI type I. The data reported here may be helpful to predict phenotype, and describes for the first time the genetic epidemiology in >95% of an entire OI population.
Figures
Similar articles
-
Lack of correlation between the type of COL1A1 or COL1A2 mutation and hearing loss in osteogenesis imperfecta patients.Hum Mutat. 2004 Aug;24(2):147-54. doi: 10.1002/humu.20071. Hum Mutat. 2004. PMID: 15241796
-
Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.Bone. 2016 Jun;87:11-8. doi: 10.1016/j.bone.2016.02.015. Epub 2016 Mar 5. Bone. 2016. PMID: 26957348
-
Comprehensive genetic analyses using targeted next-generation sequencing and genotype-phenotype correlations in 53 Japanese patients with osteogenesis imperfecta.Osteoporos Int. 2019 Nov;30(11):2333-2342. doi: 10.1007/s00198-019-05076-6. Epub 2019 Jul 29. Osteoporos Int. 2019. PMID: 31363794 Free PMC article.
-
Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans.Hum Mutat. 2007 Mar;28(3):209-21. doi: 10.1002/humu.20429. Hum Mutat. 2007. PMID: 17078022 Free PMC article. Review.
-
What every clinical geneticist should know about testing for osteogenesis imperfecta in suspected child abuse cases.Am J Med Genet C Semin Med Genet. 2015 Dec;169(4):307-13. doi: 10.1002/ajmg.c.31459. Epub 2015 Nov 14. Am J Med Genet C Semin Med Genet. 2015. PMID: 26566591 Review.
Cited by
-
Osteogenesis Imperfecta: A study of the patient journey in 13 European countries.Orphanet J Rare Dis. 2024 Sep 9;19(1):331. doi: 10.1186/s13023-024-03345-0. Orphanet J Rare Dis. 2024. PMID: 39252130 Free PMC article.
-
Analyses of Osteogenesis Imperfecta in South Korea Using the Nationwide Health Insurance Service Claim Data: A Propensity Score-Matched Study.Calcif Tissue Int. 2024 Aug 16. doi: 10.1007/s00223-024-01274-5. Online ahead of print. Calcif Tissue Int. 2024. PMID: 39150494 Review.
-
Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study.J Bone Miner Res. 2024 Sep 2;39(9):1215-1228. doi: 10.1093/jbmr/zjae112. J Bone Miner Res. 2024. PMID: 39012717 Free PMC article. Clinical Trial.
-
Reviewing hereditary connective tissue disorders: Proposals of harmonic medicolegal assessments.Int J Legal Med. 2024 Nov;138(6):2507-2522. doi: 10.1007/s00414-024-03290-4. Epub 2024 Jul 15. Int J Legal Med. 2024. PMID: 39008115 Free PMC article. Review.
-
A Retrospective Study of the Presentation, Diagnosis, Management, and Outcomes of 27 Patients with Osteogenesis Imperfecta at a Single Center in Türkiye.Med Sci Monit. 2024 May 29;30:e944364. doi: 10.12659/MSM.944364. Med Sci Monit. 2024. PMID: 38807347 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
